Type
Internal restructuring
Country
France
Region
Normandie; Haute-Normandie ; Seine-Maritime
Location of affected unit(s)
Notre-Dame-de-Bondeville
Sector
Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
20 - Manufacture of chemicals and chemical products
20 - Manufacture of chemicals and chemical products

200 jobs
Number of planned job losses
Job loss
Announcement Date
11 August 2025
Employment effect (start)
11 August 2025
Foreseen end date
1 January 2026

Description

Aspen, the South African pharmaceutical company, has announced 200 job cuts at its plant in Notre-Dame-de-Bondeville, near Rouen.

The planned job reductions are expected to be implemented through the non-renewal of temporary contracts and a series of voluntary termination agreements. Trade union representatives, notably from the CGT, have criticised the company’s strategy, citing declining activity in anticoagulant production, the loss of a major client and unsuccessful contract bids.

The site, historically dedicated to pharmaceutical production, was previously owned by Sanofi and GlaxoSmithKline and specialises in generic medicines. Employee representatives are preparing support measures, while the project is expected to unfold progressively until the end of 2025, with possible voluntary redundancies for permanent staff starting in early 2026.


Sources

Citation

Eurofound (2025), Aspen, Internal restructuring in France, factsheet number 203180, European Restructuring Monitor. Dublin, https://dev.eurofound.europa.eu/restructuring-events/detail/203180.